Enhanced Procoagulant Activity of Select Hemophilia B Causing Factor IX Variants with Emicizumab

Lee, Kyumin; Chau, Julia Q; Suber, Yani B; Sternberg, Anna R; Pishko, Allyson; George, Lindsey A.; Bhoj, Vijay; Doshi, Bhavya S; Samelson-Jones, Benjamin J

doi:10.1182/blood.2023021944

Emicizumab improves the procoagulant activity of select loss-of-function FIX variants with likely dysfunctional assembly of the intrinsic Xase complex that cause hemophilia B. FVIII-mimetics may represent an alternative non-factor therapy for select hemophilia B patients.

This content is only available as a PDF.

2024

You do not currently have access to this content.

Sign in via your Institution

Enhanced Procoagulant Activity of Select Hemophilia B Causing Factor IX Variants with Emicizumab

Article PDF first page preview

24-Hour Access

Cited By

Email alerts

ASH Publications

American Society of Hematology

Enhanced Procoagulant Activity of Select Hemophilia B Causing Factor IX Variants with Emicizumab

Article PDF first page preview

This feature is available to Subscribers Only

My Account

24-Hour Access

Cited By

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only